CIK 0001137883 · Non-accelerated filer<br>Smaller reporting company
BRAINSTORM CELL THERAPEUTICS INC.
Sign in to watch- Ticker
- BCLI
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 207273918
- Phone
- 201-488-0460
- Business address
- 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK, NY, 10019
- Former names
- BRAINSTORM CELL THERAPEUTICS INC, GOLDEN HAND RESOURCES INC, WIZBANG TECHNOLOGIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-24 | FRENKEL JACOB A Director | Grant or award | +100,000 | 343,777 | ||
| 2026-07-24 | Pitts Peter Joe Executive Chairman | Grant or award · Stock Option (Right to Buy) | +900,000 | 900,000 | ||
| 2026-02-26 | Lebovits Chaim President & CEO | Grant or award | +1,800,000 | 2,000,960 | ||
| 2026-02-26 | Yablonka Uri EVP & Chief Business Officer | Grant or award | +150,000 | 218,464 | ||
| 2026-02-26 | Patlis Alla See Remarks | Grant or award | +100,000 | 144,349 | ||
| 2026-02-26 | FRENKEL JACOB A Director | Grant or award | +200,000 | 243,777 | ||
| 2026-02-26 | ARBEL IRIT Director | Grant or award | +120,000 | 161,054 | ||
| 2026-02-26 | Bairu Menghisteab Director | Grant or award · Stock Option (Right to Buy) | +150,000 | $0.70 | $105K | 150,000 |
| 2026-02-26 | Polverino Anthony J. Director | Grant or award · Stock Option (Right to Buy) | +150,000 | $0.70 | $105K | 150,000 |
| 2026-02-26 | HARTOUNIAN HARTOUN Director | Grant or award · Stock Option (Right to Buy) | +225,000 | $0.70 | $158K | 225,000 |
| 2026-02-26 | Lindborg Stacy Director | Grant or award · Stock Option (Right to Buy) | +150,000 | $0.70 | $105K | 150,000 |
| 2026-02-26 | Naor Nir Director | Grant or award · Stock Option (Right to Buy) | +180,000 | $0.70 | $126K | 180,000 |
| 2026-02-26 | Dagher Ibrahim B. Director | Grant or award · Stock Option (Right to Buy) | +225,000 | $0.70 | $158K | 225,000 |
| 2025-01-01 | Dagher Ibrahim B. Chief Medical Officer | Grant or award | +50,000 | 66,849 | ||
| 2025-01-01 | Lebovits Chaim President & CEO | Grant or award | +120,000 | 200,960 | ||
| 2025-01-01 | FRENKEL JACOB A Director | Grant or award | +40,000 | 43,777 | ||
| 2025-01-01 | Polverino Anthony J. Director | Grant or award | +24,000 | 25,730 | ||
| 2025-01-01 | Yablonka Uri EVP & Chief Business Officer | Grant or award | +40,000 | 48,464 | ||
| 2025-01-01 | Yablonka Uri EVP & Chief Business Officer | Grant or award | +20,000 | 68,464 | ||
| 2025-01-01 | Patlis Alla See Remarks | Grant or award | +40,000 | 44,349 |
Page 1 of 7 · 127 trades